A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination

Pharmacogenetics and Genomics

Volumn 15, Issue 5, 2005, Pages 277-285

  Hulot, Jean Sébastien ^a   Villard, Eric ^a   Maguy, Ange ^a   Morel, Véronique ^a   Mir, Lluis ^b   Tostivint, Isabelle ^a   William Faltaos, Demiana ^a   Fernandez, Christine ^a   Hatem, Stéphane ^a   Deray, Gilbert ^a   Komajda, Michel ^a   Leblond, Véronique ^a   Lechat, Philippe ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Amino acid substitution; Lymphoma drug therapy; Methotrexate; Multidrug resistance associated protein 2; Pharmacogenetics

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; CARBOXYPEPTIDASE G2; COPROPORPHYRIN; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GENE PRODUCT; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 2; PREDNISONE; VINDESINE;

ADULT; ANIMAL CELL; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHO CELL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TRANSPORT; DUBIN JOHNSON SYNDROME; GENE; GENE ABCC2; GENE FUNCTION; GENE MUTATION; GENETIC TRANSFECTION; GLUCOSURIA; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; KIDNEY PROXIMAL TUBULE; LIVER CELL; MALE; NEPHROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEINURIA; SIDE EFFECT;

CRICETINAE; CRICETULUS GRISEUS;

EID: 21044455712     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01213011-200505000-00002     Document Type: Article

References (39)

1. Schinkel A, Jonker J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliver Rev 2003; 55:3-29.
2. Dean M, Rzhetshy A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11:1156-1166.
3. Kamisako T, Gabazza E, Ishihara T, Adachi Y. Molecular aspects of organic compound transport across the plasma membrane of hepatocytes. J Gastroen Hepatol 1999; 14:405-412.
4. Dubin I, Johnson F. Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. Medecine 1954; 33:155-197.
5. Toh S, Wada M, Uchiumi T, Inokuchi A, Makino Y, Horie Y, et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999; 64:739-746.
6. Mor-Cohen R, Zivelin A, Rosenberg N, Shani M, Muallem S, Seligsohn U. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J Biol Chem 2001; 276:36923-36930.
7. Paulusma C, Kool M, Bosma P, Scheffer GL, ter Borg F, Scheper RJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997; 25: 1539-1542.
8. Frank M, Doss M, DeCarvalho DG. Diagnostic and pathogenetic implications of urinary coproporphyrin excretion in the Dubin-Johnson syndrome. Hepato-gastroenterol 1990; 37:147-151.
9. Schaub TP, Kartenbeck J, Konig J, Spring H, Dorsam J, Staehler G, et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 1999; 10:1159-1169.
10. Schaub TP, Kartenbeck J, Konig J, Vogel O, Witzgall R, Kriz W, et al. Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephrol 1997; 8:1213-1221.
11. Smeets PH, Van Aubel R, Wouterse A, Van den Heuvel JJ, Russel F. Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-amminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol 2004; 15:2828-2835.
12. Russel F, Masereeuw R, Van Aubel R. Molecular aspects of renal anionic drug transport. Annu Rev Physiol 2002; 64:563-594.
13. Masereeuw R, Notenboom S, Smeets P, Wouterse A, Russel F. Impaired renal secretion of substrates for the multidrug resistance protein 2 in mutant transport-deficient (TR-) rats. J Am Soc Nephrol 2003; 14: 2741-2749.
14. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 1996; 56:4124-4129.
15. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999; 55:929-937
16. Konig J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acts. 1999; 1461:377-394.
17. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 2000; 57:760-768.
18. Balis FM, Holcenberg JS, Bleyer A. Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 1983; 41:1095-1104
19. Goldie JH, Price LA, Harrap KR. Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern. Eur J Cancer 1972; 8:409-414.
20. Stoller R, Hande K, Jacobs S, Rosenberg S, Chabner B. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New Engl J Med 1977; 297:630-634.
21. Perazella MA. Crystal-induced acute renal failure. Am J Med 1999; 106:459-465.
22. Widemann BC, Balis FM, Murphy RF, Sorensen JM, Montello MJ, O'Brien M, Adamson PC. Carboxypeptidae-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 1997; 15:2125-2134.
23. Ito K, Oleschuk CJ, Westlake C, Vasa MZ, Deeley RG, Cole SPC. Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J Biol Chem 2001; 276:38108-38114.
24. Godreau D, Vranckx R, Hatem SN. Mechanisms of action of antiarrhythmic agent bertosamil on hKv1.5 channels and outward potassium current in human atrial myocytes. J Pharmacol Exp Ther 2002; 300:612-620.
25. Orlowski S, Mir L. Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochim Biophys Acts 1993; 1154:51-63.
26. Orlowski S, Belehradek JJ, Paoletti C, Mir L. Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988; 37:4727-4733.
27. Ryu S, Kawabe T, Nada S, Yamaguchi A. Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2. J Biol Chem 2000; 275:39617-39624.
28. Ito S, Ieri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. Polymorphisms of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001; 11:175-184.
29. Hashimoto K, Uchiumi T, Konno T, Ebihara T, Nakamura T, Wada M, et al. Trafficking and functional defects by mutations of the ATP-Binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology 2002; 36:1236-1245.
30. Grim J, Chladek J, Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet 2003; 42:139-151.
31. Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004; 100:2222-2232.
32. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000; 11:383-393.
33. Gerk P, Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther 2002; 302:407-415.
34. Wada M, Toh S, Taniguchi K, et al. Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 1998; 7:203-207.
35. Tsujii H, Konig J, Rost D, Stockel B, Leuschner U, Keppler D. Exon-intror organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology 1999; 117: 653-660.
36. Konno T, Ebihara T, Hisaeda K, Uchiumi T, Nakamura T, Shirakusa, et al. Identification of domains participating in the substrate specificity and subcellular localization of the multidrug resistance proteins MRP1 and MRP2. J Biol Chem 2003; 278:22908-22917.
37. Van Aubel R, Smeets P, Peters JG, Bindels R, Russel F. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2004; 13:595-603.
38. Pinos T, Constansa JM, Palacin A, Figueras C. A new diagnostic approach to the Dubin-Johnson syndrome. Am J Gastroenteml 1990; 85:91-93.
39. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003; 8:411-424.